Southeast University   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Nanjing China (1902)

Organization Overview

First Clinical Trial
2008
NCT00939068
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Chun Pan | Department of Critical Care Medicine, Nanjing Zhong-da Hospital, School of Medicine, Southeast University | Department of Critical Care Medicine, Zhongda Hospital, School of Medicine, Southeast University | Genshan Ma | Ge Zheng | Jianfeng Xie | Medical School of South East University, China | Nanjing Chest Hospital, Medical School of Southeast University | Nanjing Zhong-Da Hospital, Southeast University | School of Biological Science and Medical Engineering, Southeast University | School of Bioscience & Medical Engineering, Southeast University | southeast univerity, China | Southeast University | Southeast University Affiliated Zhongda Hospital | Southeast University, China | southeast university zhongda hospitial | the chief of the neurology department, Zhongda Hospital of Southeast University | the Second Affiliated Hospital of Southeast University | The Second Affiliated Hospital of the Southeast University, Nanjing, China | Yuejiang Liu | Zhongda Hospital | Zhongda Hospital, Medical School, Southeast University | Zhongda Hospital, School of Medicine, Southeast Univerty | Zhongda Hospital, School of Medicinr, Southeast Univerty | Zhongda Hospital Southeast University | Zhongda hospital, Southeast university, Nanjing, China

Active Ingredients

Drugs in Phase 4 Trials (41)

acarbose (precose) (2 trials)

acetylsalicylic acid (aspirin) (1 trial)

clopidogrel (plavix) (1 trial)

coartem (1 trial)

coniel (1 trial)

dexmedetomidine (precedex) (5 trials)

dezocine (dalgan) (1 trial)

dihydroqinghaosu (1 trial)

dobesilic acid (1 trial)

flumatinib (1 trial)

fosinopril (monopril) (1 trial)

glimepiride (amaryl) (1 trial)

hepatitis b immune globulin (human) (BayHep B) (1 trial)

hepatitis b vaccine (recombinant) (recombivax) (1 trial)

hydrochlorothiazide (esidrix) (1 trial)

hydrocortisone (solu-cortef) (1 trial)

imipenem (primaxin) (1 trial)

lamivudine (epivir) (1 trial)

lumefantrine (Coartem) (1 trial)

mitiglinide (1 trial)

morphine (1 trial)

nalbuphine (nubain) (2 trials)

nicorandil (2 trials)

octreotide (sandostatin) (1 trial)

oxymatrine (1 trial)

piperaquinoline (1 trial)

propofol (diprivan) (4 trials)

remifentanil (ultiva) (3 trials)

saxagliptin (onglyza) (2 trials)

sevoflurane (ultane) (2 trials)

sodium bicarbonate (1 trial)

sodium chloride (3 trials)

telbivudine (tyzeka) (2 trials)

tenofovir (viread) (1 trial)

terlipressin (2 trials)

thiamine (1 trial)

ticagrelor (brilinta) (1 trial)

urea (1 trial)

vitamin c (1 trial)

warfarin (coumadin) (1 trial)

xuebijing (2 trials)

Drugs in Phase 3 Trials (17)

anlotinib (1 trial)

azacitidine (vidaza) (2 trials)

cladribine (leustatin) (1 trial)

decitabine plus modified bucy (1 trial)

dicycloplatin (1 trial)

epirubicin (ellence) (1 trial)

fentanyl (Innovar) (2 trials)

fludarabine (fludara) (1 trial)

heparin (liquaemin) (1 trial)

idarubicin (idamycin) (1 trial)

lenalidomide (revlimid) (2 trials)

methylprednisolone (medrol) (1 trial)

omacetaxine (synribo) (1 trial)

penpulimab (1 trial)

shenfu zhusheye (1 trial)

sivelestat (1 trial)

ytttrium-90 microspheres (1 trial)

Drugs in Phase 2 Trials (18)

arsenic trioxide (trisenox) (1 trial)

cyclophosphamide (cytoxan) (1 trial)

donafenib (1 trial)

doxorubicin (Doxil) (2 trials)

envafolimab (1 trial)

etoposide (vepesid) (1 trial)

gemcitabine (gemzar) (1 trial)

lenvatinib (lenvima) (1 trial)

l-glutamine (1 trial)

midazolam (versed) (2 trials)

oxaliplatin (eloxatin) (1 trial)

prednisone (meticorten) (1 trial)

ringer's lactate (1 trial)

sailuotong (1 trial)

sintilimab (1 trial)

thymosin alpha-1 (1 trial)

tislelizumab (1 trial)

vincristine (oncovin) (1 trial)

Drugs in Phase 1 Trials (1)

hyaluronic acid (1 trial)

Drugs in Other Trials (10)

125-iodine (1 trial)

apatinib (1 trial)

camrelizumab (1 trial)

daptomycin (cubicin) (1 trial)

esomeprazole (nexium) (1 trial)

ethiodol (1 trial)

mosapride (citrate) (1 trial)

polyethylene glycol (1 trial)

simethicone (1 trial)

sorafenib (nexavar) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 4)

Adrenal Insufficiency (Phase 4)

Atrial Fibrillation (Phase 4)

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Cognitive Dysfunction (Phase 4)

Communicable Diseases (Phase 4)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Critical Illness (Phase 1)

Delirium (Phase 4)

Dementia (Phase 2)

Dementia, Vascular (Phase 2)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 2 (Phase 4)

Diabetic Retinopathy (Phase 4)

Disseminated Intravascular Coagulation (Phase 3)

Heart Diseases (Phase 4)

Hemorrhage (Phase 4)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 4)

Hepatitis B, Chronic (Phase 4)

Hepatitis, Chronic (Phase 4)

Hypertension (Phase 4)

Infarction (Phase 4)

Infections (Phase 4)

Kidney Diseases (Phase 4)

Leukemia (Phase 4)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 3)

Malaria (Phase 4)

Myocardial Infarction (Phase 4)

Myocardial Ischemia (Phase 4)

Osteoarthritis (Phase 1)

Osteoarthritis, Knee (Phase 1)

Pain, Postoperative (Phase 4)

Postoperative Complications (Phase 4)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 4)

Pregnancy Complications (Phase 4)

Renal Insufficiency, Chronic (Phase 4)

Respiratory Distress Syndrome (Phase 4)

Respiratory Distress Syndrome, Newborn (Phase 4)

Retinal Diseases (Phase 4)

Rheumatic Heart Disease (Phase 2)

Sepsis (Phase 4)

Shock (Phase 4)

Shock, Septic (Phase 4)

ST Elevation Myocardial Infarction (Phase 4)

Syndrome (Phase 4)

Toxemia (Phase 4)

Viremia (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 63
  • # of Trial APIs: 87